Patients currently enrolled in other clinical trials testing a therapeutic intervention
Patients must not plan to participate in any other clinical trials while receiving treatment on this study or being followed post-protocol therapy
Has participated in Merck MK- (pembrolizumab) clinical trials
Participation in other clinical trials within at least  weeks of the first ORH- dose;
Patients being treated with any other experimental agents/clinical trials are not eligible for participation; if the patient is on any investigational agent, a wash-out period of minimum  weeks prior to registration is mandatory for the patient to be eligible for the study
No concurrent treatment on another clinical trial; supportive care trials or nontreatment trials, e.g. quality of life, are allowed
Clinical trials prior to enrollment are allowed, as long as no brain directed therapy was included (current treatment trials are exclusionary)
Participant in other clinical trials
Concurrent participation in other investigational drug trials.
Participation in other clinical trials with the same primary endpoint
Subject is participating in any other therapeutic clinical study (observational or registry trials are allowed)
Patients are eligible if they undergo a targeted treatment recommended by the Molecular Tumor Board, excluding clinical trials
Participating in any other clinical trials using an investigational product.
Simultaneous participation in other therapeutic clinical trials will not be allowed
In accordance with National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) policy, protocol treatment is to begin within  working days of patient registration
Measurable disease by the criteria proposed by the acquired immunodeficiency syndrome (AIDS) Clinical Trials Group Oncology Committee (for KS)
Simultaneous participation in other therapeutic clinical trials will be allowed
Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.
EXCLUSION CRITERIA FOR REGISTRATION: subjects should not be participating in other clinical trials of interventions designed to reduce risk of ovarian cancer recurrence or plan to receive off protocol maintenance therapy (e.g. paclitaxel or bevacizumab)
Any other investigational treatments within  weeks prior to and during study; includes participation in any medical device or other therapeutic intervention clinical trials
Enrolled in another clinical trial with a targeted endpoint of treating the patients cancer (observational trials are acceptable)
Subjects who have recently been enrolled in other experimental clinical trials of\n             investigational agents
Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed
Patients who currently are participating in other phase III therapeutic clinical trials and/or who have participated in other phase III therapeutic clinical trials in the previous  days
Participation in concurrent clinical trials evaluating treatment intervention(s)
Not be receiving neoadjuvant hormonal or chemotherapy (other clinical trials)
Participation in the active phase of other clinical trials of investigational agents in which last study treatment was administered within  weeks prior to randomization
Participant has participated in clinical trials of experimental agents within  weeks prior to randomization
Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed
Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), and imaging trials, are allowed
Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.
Patients enrolled in other clinical trials must have received their last treatment at least  weeks prior to enrollment
Simultaneous participation in other therapeutic clinical trials will not be allowed
Patients receiving or participating on any other experimental agents/clinical trials are not eligible for participation
Concurrent treatment on another clinical trial; supportive care trials or non-treatment (i.e. quality of life) are allowed
Patients who have participated in other interventional (treatment-related) clinical trials within  days of enrollment are excluded
Patients who are enrolled in other symptom management or symptom clinical trials
Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed
Patients who are enrolled in a national/international cooperative group trials
Treatment with any known non-marketed drug substance or experimental therapy within  weeks prior to enrollment, or currently participating in any other interventional clinical study for NHL or any other illness (except observational and registry trials)
Participation in clinical drug trials within  weeks
Registered with Clinical Trials Office at Karmanos Cancer Institute/Wayne State University
Concurrent treatment on another clinical trial; supportive care trials, surgical clinical trials, or non-treatment trials, e.g. quality of life (QOL), are allowed
Simultaneous participation in other therapeutic clinical trials will not be allowed
Treatment with any known non-marketed drug substance or experimental therapy within  weeks prior to enrollment, or currently participating in any other interventional clinical study for NHL or any other illness (except observational, prevention, and/or registry trials)
Patients must not co-enroll on other treatment trials
Concurrent treatment on another clinical trial; supportive care trials or non-therapeutic trials (i.e. quality of life) are allowed
Participants may be enrolled on other treatment-based clinical trials but may not be enrolled on any other weight loss trials
Patients enrolled on other supportive care intervention trials
Individuals who are enrolled on oral chemotherapy clinical trials will also be excluded
Patients who are enrolled in other clinical trials that have symptom management as primary outcome
Patients who are enrolled in other symptom management clinical trials
Patients may concurrently participate in other therapeutic clinical trials
Patients are permitted to participate in other clinical trials while participating in this trial
Participants in other ongoing clinical trials are eligible for this study
No concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, insulin-like growth factor  (IGF-) or their receptors
Registered with the clinical trials office of the Karmanos Cancer Center/Wayne State University
Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study
Patients preparing to receive therapy for pancreas cancer, including patients enrolled in HRPO#  or other clinical trials, are eligible
Patients must not be participating or plan to participate in other clinical trials that involve investigational systemic cancer treatments or investigational uses of CSF during their first  months after registration
Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed; patients may be enrolled to other clinical trials after completing all of the baseline interventions and measures
Be interventional trials